Jakafi

Generic name: ruxolitinib [ RUX-oh-LI-ti-nib ]

Drug class: Janus kinase (JAK) inhibitors

Dosage form: Tablet

Route of administration: Oral

Dose: Typically, 5 mg to 25 mg twice daily, depending on the condition and patient response.

Mechanism of action: Jakafi inhibits Janus kinase (JAK) 1 and 2, enzymes involved in the signaling pathways that influence hematopoiesis and immune function. By blocking these pathways, Jakafi reduces inflammation and abnormal blood cell production associated with certain hematologic conditions.

Drug usage cases: Jakafi is used to treat intermediate or high-risk myelofibrosis, polycythemia vera in patients resistant to or intolerant of hydroxyurea, and acute graft-versus-host disease.

Drug contra indications: Jakafi should not be used in patients with severe hypersensitivity to ruxolitinib or any component of the formulation. Caution is advised in patients with severe renal or hepatic impairment.

Side effects: Common side effects include anemia, thrombocytopenia, and dizziness. Serious side effects may include:

• Serious infections: Increased risk of bacterial, fungal, and viral infections.
• Thrombocytopenia: Risk of significant decrease in platelet count.
• Anemia: Risk of severe decrease in red blood cells.
• Hepatotoxicity: Potential for liver enzyme elevation and liver damage.

Warnings: Jakafi can increase the risk of serious infections, requiring vigilance and prompt treatment if symptoms arise. Regular monitoring of blood counts is essential to manage anemia and thrombocytopenia. Liver function tests should be conducted periodically to monitor for hepatotoxicity.

Use during pregnancy or breastfeeding: The safety of Jakafi during pregnancy is not well established, and it should be used only if the potential benefit justifies the potential risk to the fetus. It is unknown whether ruxolitinib is excreted in human milk, so caution should be exercised when administered to breastfeeding mothers.